OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent

  Out-of-Stock 

Purchase at Moment

Payment After 3 Month

Quarterly repayment with the lowest fees Recharge every three months, 200 million tomman for each season.

Features:

Dual Therapy Stent

Netherlands Made

Stainless Steel 316L

CD34 antibodies

Bioabsorbable Polymer

Sirolimus Drug

 
Notify me when available

  • 0
  • Out stock
  • Free

Pay in installments

Choose your plan:

Current plan: 3Month

Description: 30+3

Down payment: $0.00 (25.00%)

Number of payments: 3

Tax: $0.00

Amount of payment: $0.00

Overpayment: $0.00

Total: $0.00

Current plan: Cash

Description: نقدی

Down payment: $0.00 (0.00%)

Number of payments: 1

Tax: $0.00

Amount of payment: $0.00

Overpayment: $0.00

Total: $0.00

Description

Combo Plus Dual Therapy Stent

COMBO Plus is more than just a drug-eluting stent (DES). It is a combination of traditional DES components with the addition of a biological coating.

 

OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent

 

Function of the Biological Coating

CD34 antibodies are immobilized on the surface of the stent and capture circulating endothelial progenitor cells (EPCs). The captured EPCs are triggered by sheer stress from the circulating blood and other cell signals to differentiate and mature into endothelial cells. COMBO Plus is the only stent with a biological coating that actively repairs the vessel morphology.

  

OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent

 

Sirolimus Release from a Bioabsorbable Polymer

The proprietary bioabsorbable polymer is coated on the abluminal side of the stent, allowing for directional drug release in 30 days and polymer absorption in 90 days. 

 

OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent

 

Dual Helix Stent Design

COMBO’s dual helix design is engineered for:

  •   Excellent radial strength
  •   Large side branch access
  •   Natural conformability

 

OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent

 

Key clinical findings

Unique 24-Month Neointimal Regression

A mechanistic study demonstrated that repeat OCT follow-up in the same patients showed a significant decrease in neointimal thickness and volume at 24-month compared to 9-month follow-up, indicative of neointimal maturation and stability. 

 

OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent

 

Low Event Rates demonstrate Safe Results

Studies have consistently shown low event rates. In the REMEDEE Registry (N=1000), 1-year results in an all comers' population showed effectiveness with low target lesion revascularization, and safety with low rates of cardiac death, myocardial infarction and stent thrombosis. 

 

OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent

 

Technical Specifications

 

OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent

 

OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent

 

OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent



Reference : 0

Data sheet

  • Holland

Specific References

New product



Leave a comment about this product

Write your review

Write your review

OrbusNeich Medical B.V - Combo Plus Dual Therapy Stent

Write your review